Gerald E. Piontek

Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy

Klas Kärre, Hans Ljunggren, Gerald E. Piontek et al. · Nature · 1986 · 2.1K citations · Full text

Histocompatibility, Lymphoid Neoplasia, Cancer Immunosurveillance +9

YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage.

Gerald E. Piontek, K. Taniguchi, Hans‐Gustaf Ljunggren et al. · The Journal of Immunology · 1985 · 168 citations

Histocompatibility, Adaptive Immune System, Immunology +19

Characteristics of the chemotactic factor-mediated cell swelling response of tumor cells.

John Wass, James Varani, Gerald E. Piontek et al. · PubMed · 1981 · 25 citations

Immunology, Immunoediting, Cell Culture +20

Responses of normal and malignant cells to collagen, collagen-derived peptides and the C5-related tumor cell chemotactic peptide

John Wass, James Varani, Gerald E. Piontek et al. · Cell Differentiation · 1981 · 21 citations · Full text

Tumor Biology, Malignant Cells, Peptide Library +9

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. 1986.

Klas Kärre, Hans Ljunggren, Gerald E. Piontek et al. · PubMed · 2005 · 21 citations

Histocompatibility, Adaptive Immune System, Immune Regulation +21